Maravai LifeSciences (MRVI) Competitors

Maravai LifeSciences logo
$4.20 +0.08 (+1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$4.20 +0.00 (+0.12%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MRVI vs. RARE, RNA, SWTX, ADMA, OGN, BHVN, PTCT, ALVO, SRRK, and ACLX

Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Ultragenyx Pharmaceutical (RARE), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), ADMA Biologics (ADMA), Organon & Co. (OGN), Biohaven (BHVN), PTC Therapeutics (PTCT), Alvotech (ALVO), Scholar Rock (SRRK), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.

Maravai LifeSciences vs.

Maravai LifeSciences (NASDAQ:MRVI) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking and media sentiment.

Maravai LifeSciences currently has a consensus price target of $10.28, indicating a potential upside of 146.85%. Ultragenyx Pharmaceutical has a consensus price target of $92.43, indicating a potential upside of 120.54%. Given Maravai LifeSciences' higher probable upside, equities analysts plainly believe Maravai LifeSciences is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maravai LifeSciences
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.36
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

In the previous week, Ultragenyx Pharmaceutical had 10 more articles in the media than Maravai LifeSciences. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 5 mentions for Maravai LifeSciences. Ultragenyx Pharmaceutical's average media sentiment score of 0.02 beat Maravai LifeSciences' score of -0.10 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maravai LifeSciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Ultragenyx Pharmaceutical
3 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Maravai LifeSciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciences$288.95M3.64-$119.03M-$1.64-2.54
Ultragenyx Pharmaceutical$434.25M8.91-$606.64M-$6.47-6.48

Maravai LifeSciences has a net margin of -81.13% compared to Ultragenyx Pharmaceutical's net margin of -106.93%. Maravai LifeSciences' return on equity of -6.61% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Maravai LifeSciences-81.13% -6.61% -3.45%
Ultragenyx Pharmaceutical -106.93%-187.12%-37.55%

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 0.6% of Maravai LifeSciences shares are held by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maravai LifeSciences has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Ultragenyx Pharmaceutical received 772 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 77.44% of users gave Ultragenyx Pharmaceutical an outperform vote while only 62.63% of users gave Maravai LifeSciences an outperform vote.

CompanyUnderperformOutperform
Maravai LifeSciencesOutperform Votes
62
62.63%
Underperform Votes
37
37.37%
Ultragenyx PharmaceuticalOutperform Votes
834
77.44%
Underperform Votes
243
22.56%

Summary

Ultragenyx Pharmaceutical beats Maravai LifeSciences on 11 of the 18 factors compared between the two stocks.

Get Maravai LifeSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRVI vs. The Competition

MetricMaravai LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.05B$6.92B$5.81B$9.18B
Dividend YieldN/A2.88%5.26%4.00%
P/E Ratio-2.549.5625.8419.35
Price / Sales3.64323.63473.6677.53
Price / Cash52.2775.4646.0938.88
Price / Book1.335.567.295.04
Net Income-$119.03M$123.72M$3.19B$222.76M
7 Day Performance-9.06%0.57%1.30%1.46%
1 Month Performance-8.26%3.29%5.49%4.43%
1 Year Performance-19.13%3.19%23.75%19.10%

Maravai LifeSciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRVI
Maravai LifeSciences
4.1729 of 5 stars
$4.20
+1.9%
$10.28
+144.8%
-19.8%$1.06B$288.95M-2.56610
RARE
Ultragenyx Pharmaceutical
4.6655 of 5 stars
$45.03
-0.7%
$92.43
+105.3%
-1.0%$4.15B$522.75M-6.951,276Earnings Report
Analyst Forecast
News Coverage
Gap Up
RNA
Avidity Biosciences
1.5979 of 5 stars
$34.08
-2.4%
$65.80
+93.1%
+148.8%$4.06B$9.56M-11.83190
SWTX
SpringWorks Therapeutics
1.3545 of 5 stars
$53.93
+33.9%
$70.00
+29.8%
+31.1%$4.00B$5.45M-13.85230Analyst Forecast
Insider Trade
News Coverage
High Trading Volume
ADMA
ADMA Biologics
3.7944 of 5 stars
$16.65
-0.4%
$21.25
+27.7%
+211.0%$3.94B$258.21M59.55530Positive News
OGN
Organon & Co.
4.8442 of 5 stars
$15.05
+2.9%
$21.33
+41.8%
+1.2%$3.88B$6.26B2.9910,000Earnings Report
Analyst Forecast
News Coverage
BHVN
Biohaven
3.6703 of 5 stars
$38.28
-0.4%
$63.00
+64.6%
-11.1%$3.88BN/A-4.10239Analyst Forecast
Short Interest ↓
PTCT
PTC Therapeutics
3.7028 of 5 stars
$49.99
+1.0%
$57.85
+15.7%
+105.7%$3.85B$900.66M-8.411,410Analyst Forecast
ALVO
Alvotech
1.9846 of 5 stars
$12.62
-2.2%
$18.00
+42.6%
-18.4%$3.80B$93.38M-6.811,026Analyst Forecast
SRRK
Scholar Rock
4.0471 of 5 stars
$38.69
-3.2%
$40.43
+4.5%
+145.1%$3.62B$33.19M-16.47140Positive News
Gap Down
ACLX
Arcellx
1.4131 of 5 stars
$67.02
+0.2%
$105.93
+58.1%
+4.3%$3.61B$110.32M-94.1380Short Interest ↑
Negative News

Related Companies and Tools


This page (NASDAQ:MRVI) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners